Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 onderzoek: Late cardiovascular toxicity in long-term childhood cancer survivors

Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 onderzoek: Late cardiovascular toxicity in long-term childhood cancer survivors - SKION LATER Q2008 - cardiology

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47898

Enrollment

3900

Registered

2012-07-03

Start date

2016-05-04

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hartfailure in childhood cancer survivors late cardiotoxic effects of treatment for childhood cancer

Interventions

None listed

Eligibility

Age

12 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients who were treated for childhood cancer (before age 18) in one of the Pediatric Oncology Centers between 1960 and 2001 and who survived for at least 5 years after diagnosis will be included in the SKION LATER study. Participating centres are located in Amsterdam (VU University Medical Center (VUMC)), Groningen (Children's Cancer Center/ University Medical Center Groningen (UMCG)), Rotterdam (Rotterdam Erasmus MC-Sophia (REMC-S), Nijmegen (University Medical Center Nijmegen (UMCN)), Leiden (Leiden University Medical Center (LUMC) and Utrecht (Princess Máxima Center for Pediatric Oncology (PMC)). From this cohort, 3400 childhood cancer survivors will be asked to participate in the cardiology study secondly, 500 controls will be recruited, siblings of the included patients.

Exclusion criteria

Exclusion criteria: diagnosis of childhood cancer with survival less than 5 years, age at diagnosis >17 years or diagnosis while residing in foreign country no cardiotoxic treatment

Design outcomes

Primary

Measure	Time frame
1- Prevalence of abnormal systolic function (SF) in CCS treated with possible cardiotoxic treatment compared to siblings 2- Prevalence of other cardiac abnormalities, cardiovascular risk factors, abnormal biomarkers, ECG abnormalities compared to siblings 3- Treatment related risk factors for abnormal diagnostic values 4- Diagnostic value of echocardiographic measurements and biomarkers for an abnormal systolic or diastolic function	—

Measure

Time frame

1- Prevalence of abnormal systolic function (SF) in CCS treated with possible cardiotoxic treatment compared to siblings 2- Prevalence of other cardiac abnormalities, cardiovascular risk factors, abnormal biomarkers, ECG abnormalities compared to siblings 3- Treatment related risk factors for abnormal diagnostic values 4- Diagnostic value of echocardiographic measurements and biomarkers for an abnormal systolic or diastolic function

—

Countries

Netherlands

Outcome results